Zacks: AEterna Zentaris Inc. (AEZS) Given $3.50 Consensus Target Price by Analysts

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus target price of $3.50 for the company and are expecting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 183 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

Several analysts recently issued reports on the company. Zacks Investment Research raised AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Thursday. Maxim Group set a $4.00 target price on AEterna Zentaris and gave the stock a “buy” rating in a research note on Wednesday, March 28th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of AEterna Zentaris in a research note on Thursday, March 29th. Finally, ValuEngine raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.

An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. boosted its stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 56,800 shares of the biopharmaceutical company’s stock after buying an additional 46,500 shares during the period. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 at the end of the most recent reporting period. 1.91% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ AEZS opened at $1.35 on Thursday. AEterna Zentaris has a 1 year low of $0.78 and a 1 year high of $3.75.

TRADEMARK VIOLATION NOTICE: “Zacks: AEterna Zentaris Inc. (AEZS) Given $3.50 Consensus Target Price by Analysts” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3340927/zacks-aeterna-zentaris-inc-aezs-given-3-50-consensus-target-price-by-analysts.html.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency.

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Franko Market Capitalization Tops $115,130.00
Franko Market Capitalization Tops $115,130.00
Pluristem Therapeutics  PT Set at $3.00 by Maxim Group
Pluristem Therapeutics PT Set at $3.00 by Maxim Group
Ripio Credit Network  Trading 28.5% Higher  Over Last Week
Ripio Credit Network Trading 28.5% Higher Over Last Week
Triaconta  Price Hits $6.44 on Top Exchanges
Triaconta Price Hits $6.44 on Top Exchanges
Sysco  and Domino’s Pizza  Critical Comparison
Sysco and Domino’s Pizza Critical Comparison
Universal Display  and AVX  Head to Head Comparison
Universal Display and AVX Head to Head Comparison


© 2006-2018 Ticker Report. Google+.